Adventris Analysis: $500K Raised
What is Adventris?
Adventris is a biotechnology company specializing in cancer immunotherapy, developing innovative treatments to enhance the immune system's ability to fight cancer.
Employees
7
Founded
2022
Business Model
Biotechnology revenue from cancer immunotherapy, partnerships, and funding rounds.
Product Features & Capabilities
- cancer vaccines targeting specific mutations, first product focuses on lung cancer and KRAS mutation, aims to train the immune system to recognize and eliminate cancer cells, potential for annual vaccinations to prevent cancer deaths, off-the-shelf vaccine for KRAS mutation, annual pan-cancer vaccin
How much Adventris raised
Pre-Seed - $500,000
April 5, 2023Lead Investor: Y Combinator
Who are the founders of Adventris
Market Focus
Adventris primarily focuses on the biotechnology industry, specifically in cancer immunotherapy.
Competitors Overview
Adventris operates in the cancer immunotherapy market and faces competition from several notable companies:
- BeiGene: Specializes in developing targeted and immune-oncology drugs against cancer. It has raised significant funding of $172 million, which allows for extensive research and develop
Investors
- Y Combinator
- Johns Hopkins Technology Ventures
- Refactor Capital
See something that needs updating? Suggest edits to this profile.